Advanced search
Start date
Betweenand
Related content
(Reference retrieved automatically from Web of Science through information on FAPESP grant and its corresponding number as mentioned in the publication by the authors.)

Main differences between two highly effective lipid-lowering therapies in subclasses of lipoproteins in patients with acute myocardial infarction

Full text
Author(s):
Show less -
Pinto, Leticia C. S. [1] ; Mello, Ana P. Q. [1] ; Izar, Maria C. O. [1] ; Damasceno, Nagila R. T. [2] ; Neto, Antonio M. F. [3] ; Franca, Carolina N. [4] ; Caixeta, Adriano [1] ; Bianco, Henrique T. [1] ; Povoa, Rui M. S. [1] ; Moreira, Flavio T. [1] ; Bacchin, Amanda S. F. [1] ; Fonseca, Francisco A. [1]
Total Authors: 12
Affiliation:
[1] Univ Fed Sao Paulo, UNIFESP, Escola Paulista Med, Setor Lipides Aterosclerose & Biol Vasc, Rua Loefgren 1350, BR-04040001 Sao Paulo, SP - Brazil
[2] Univ Sao Paulo, Fac Saude Publ, USP, Sao Paulo - Brazil
[3] Univ Sao Paulo, Inst Fis, USP, Sao Paulo - Brazil
[4] Univ Santo Amaro, UNISA, Sao Paulo - Brazil
Total Affiliations: 4
Document type: Journal article
Source: LIPIDS IN HEALTH AND DISEASE; v. 20, n. 1 SEP 29 2021.
Web of Science Citations: 0
Abstract

Background: Large observational studies have shown that small, dense LDL subfractions are related to atherosclerotic cardiovascular disease. This study assessed the effects of two highly effective lipid-lowering therapies in the atherogenic subclasses of lipoproteins in subjects with ST-segment elevation myocardial infarction (STEMI). Methods: Patients of both sexes admitted with their first myocardial infarction and submitted to pharmacoinvasive strategy (N = 101) were included and randomized using a central computerized system to receive a daily dose of simvastatin 40 mg plus ezetimibe 10 mg or rosuvastatin 20 mg for 30 days. Intermediate-density lipoprotein (IDL) and low-density lipoprotein (LDL) subfractions were analysed by polyacrylamide gel electrophoresis (Lipoprint System) on the first (D1) and 30th days (D30) of lipid-lowering therapy. Changes in LDL and IDL subfractions between D1 and D30 were compared between the lipid-lowering therapies (Mann-Whitney U test). Results: The classic lipid profile was similar in both therapy arms at D1 and D30. At D30, the achievement of lipid goals was comparable between lipid-lowering therapies. Cholesterol content in atherogenic subclasses of LDL (p = 0.043) and IDL (p = 0.047) decreased more efficiently with simvastatin plus ezetimibe than with rosuvastatin. Conclusions: Lipid-lowering therapy with simvastatin plus ezetimibe was associated with a better pattern of lipoprotein subfractions than rosuvastatin monotherapy. This finding was noted despite similar effects in the classic lipid profile and may contribute to residual cardiovascular risk. (AU)

FAPESP's process: 12/51692-7 - Role of adaptative immunity on the progress of ischemic heart disease after acute myocardial infarction
Grantee:Francisco Antonio Helfenstein Fonseca
Support Opportunities: Research Projects - Thematic Grants
FAPESP's process: 14/50983-3 - INCT 2014: complex fluids
Grantee:Antonio Martins Figueiredo Neto
Support Opportunities: Research Projects - Thematic Grants